Researchers have made a significant breakthrough in the fight against antibiotic-resistant strains of gonorrhoea, a sexually transmitted infection that affects over half a million people in the U.S. each year. For the first time in 30 years, a promising new antibiotic treatment called gepotidacin has been discovered, offering hope in the battle against drug-resistant strains of the bacteria responsible for gonorrhoea.
Gonorrhoea, caused by the bacterium Neisseria gonorrhoeae, has developed resistance to nearly all existing antibiotic treatments, leaving healthcare providers with limited options for effective therapy. The World Health Organization has classified gonorrhoea as a “high” priority pathogen due to the rising global threat of antibiotic resistance. With between 600,000-700,000 cases diagnosed annually in the U.S., finding alternative treatments is crucial to controlling the spread of the infection.
Gepotidacin, recently approved by the FDA for the treatment of urinary tract infections, has shown promising results in clinical trials for gonorrhoea. In a phase 3 trial involving over 600 patients across six countries, including the U.K. and the U.S., gepotidacin was found to be as effective as the current standard treatment, even against drug-resistant strains of Neisseria gonorrhoeae.
The mechanism of action of gepotidacin involves stopping bacterial DNA replication, preventing the bacteria from dividing and multiplying. This oral treatment eliminates the need for injections, making it more convenient and accessible for patients. The study also reported no significant side effects associated with gepotidacin, highlighting its safety profile as a potential treatment for gonorrhoea.
The findings of the study, published in The Lancet and presented at the 2025 European Society of Clinical Microbiology and Infectious Diseases conference, represent a significant step forward in the fight against antibiotic resistance in gonorrhoea. With the rise of drug-resistant infections, gepotidacin offers a much-needed alternative to existing therapies and a glimmer of hope in the ongoing battle against antimicrobial resistance.
